ReviewRespiratory research2019
Effectiveness of long-term using statins in COPD - a network meta-analysis.
Review in Respiratory research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 4 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Statins for the prevention of exacerbations in COPD: a systematic review and meta-analysis of randomized controlled trials.Systematic reviews · 2026Pooled it
- Comparative effectiveness of statins for chronic obstructive pulmonary disease patients with pulmonary hypertension: systematic review and network meta-analysis.Frontiers in medicine · 2025Pooled it
- A Systematic Review and Meta-Analysis on the Safety and Efficacy of Rosuvastatin as an Adjunctive Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2025Pooled it
- Pooled it
- Association between statins and chronic obstructive pulmonary disease: insights from cohort and genetic validation.Journal of thoracic disease · 2026Article
- COPD and Cardiovascular Diseases: Biomarker-Guided Stratification and Therapeutic Perspectives.Journal of clinical medicine · 2025Review
- Muscle Wasting and Treatment of Dyslipidemia in COPD: Implications for Patient Management.Biomedicines · 2025Review
- The Aging Lung: Exploring Multimorbidity Patterns and Their Clinical Implications: A Narrative Review.Current issues in molecular biology · 2025Review
- Endothelial dysfunction in chronic obstructive pulmonary disease: an update on mechanisms, assessment tools and treatment strategies.Frontiers in medicine · 2025Review
- Genetic association of lipids and lipid lowering drug target genes with sarcoidosis.Scientific reports · 2024Article
- Extrapulmonary Comorbidities Associated with Chronic Obstructive Pulmonary Disease: A Review.International journal of chronic obstructive pulmonary disease · 2024Review
- Association between statin use on delirium and 30-day mortality in patients with chronic obstructive pulmonary disease in the intensive care unit.European journal of medical research · 2023Article
- Pulmonary Function in Adults With Type 2 Diabetes With and Without Obesity.CHEST pulmonary · 2023Article
- The Association of Lung Function and Carotid Intima-Media Thickness in a Japanese Population: The Tohoku Medical Megabank Community-Based Cohort Study.Journal of atherosclerosis and thrombosis · 2023Article
- The Role of Smoking in the Mechanisms of Development of Chronic Obstructive Pulmonary Disease and Atherosclerosis.International journal of molecular sciences · 2023Review
- The Relationship of Cholesterol Responses to Mitochondrial Dysfunction and Lung Inflammation in Chronic Obstructive Pulmonary Disease.Medicina (Kaunas, Lithuania) · 2023Review
- Pleotropic effects of statins: the dilemma of wider utilization of statin.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2023Review
- Simvastatin and dehydroepiandrosterone sulfate effects against hypoxic pulmonary hypertension are not additive.Physiological research · 2022Article
- Article
- Regulatory roles of external cholesterol in human airway epithelial mitochondrial function through STARD3 signalling.Clinical and translational medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the effectiveness of long-term treatment of statins for chronic obstructive pulmonary disease (COPD), and to answer which one is better.
methodsGeneral meta-analysis was performed to produce polled estimates of the effect of mortality, inflammatory factors, and lung function index in COPD patients by the search of PubMed, Web of Science, Embase, and China National Knowledge Infrastructure for eligible studies. A network meta-analysis was performed to synthetically compare the effectiveness of using different statins in COPD patients.
resultsGeneral meta-analysis showed that using statins reduced the risk of all-cause mortality, heart disease-related mortality and COPD acute exacerbation (AECOPD) in COPD patients, the RR (95% CI) were 0.72 (0.63,0.84), 0.72 (0.53,0.98) and 0.84 (0.79,0.89), respectively. And using statins reduced C-reactive protein (CRP) and pulmonary hypertension (PH) in COPD patients, the SMD (95% CI) were - 0.62 (- 0.52,-0.72) and - 0.71 (- 0.85,-0.57), respectively. Network meta-analysis showed that Fluvastatin (97.7%), Atorvastatin (68.0%) and Rosuvastatin (49.3%) had higher cumulative probability than other statins in reducing CRP in COPD patients. Fluvastatin (76.0%) and Atorvastatin (75.4%) had higher cumulative probability than other satins in reducing PH in COPD patients.
conclusionsUsing statins can reduce the risk of mortality, the level of CRP and PH in COPD patients. In addition, Fluvastatin and Atorvastatin are more effective in reducing CRP and PH in COPD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.